<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01829971</url>
  </required_header>
  <id_info>
    <org_study_id>MRX34-101</org_study_id>
    <nct_id>NCT01829971</nct_id>
  </id_info>
  <brief_title>A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection</brief_title>
  <official_title>A Multicenter Phase I Study of MRX34, MicroRNA miR-RX34 Liposomal Injection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mirna Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Cancer Prevention Research Institute of Texas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Mirna Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a study to evaluate the safety of MRX34 in patients with primary liver cancer or
      other selected solid tumors or hematologic malignancies. The drug is given intravenously, for
      5 days in a row and then two weeks off.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase I, open-label, multicenter, dose-escalation study to investigate the safety,
      Pharmacokinetics and Pharmacodynamics of the micro ribonucleic acid (microRNA) MRX34, in
      patients with unresectable primary liver cancer or advanced or metastatic cancer with or
      without liver involvement or hematologic malignancies. MRX34 will be administered daily x 5
      with 2 weeks off (total of 21 days) for 3 cycles followed by a no-treatment observation
      period.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Five immune related serious adverse events
  </why_stopped>
  <start_date>April 2013</start_date>
  <completion_date type="Anticipated">May 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) for MRX34 and the recommended phase 2 dose (RPh2D)</measure>
    <time_frame>18 months</time_frame>
    <description>Dose-limiting toxicity (DLT) in 3-6 patients at the end of one treatment cycle</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Peak blood concentration and Area Under the Curve (AUC) of MRX34 after IV dosing</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of patients with evidence of clinical activity of MRX34</measure>
    <time_frame>18 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">155</enrollment>
  <condition>Primary Liver Cancer</condition>
  <condition>SCLC</condition>
  <condition>Lymphoma</condition>
  <condition>Melanoma</condition>
  <condition>Multiple Myeloma</condition>
  <condition>Renal Cell Carcinoma</condition>
  <condition>NSCLC</condition>
  <arm_group>
    <arm_group_label>MRX34</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single agent MRX34</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MRX34</intervention_name>
    <description>micro RNA therapy</description>
    <arm_group_label>MRX34</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Aged ≥ 18 years

          2. Patients with histologically confirmed viral related hepatocellular, SCLC,
             non-cutaneous/ non-uveal melanoma, ovarian, TNBC, Sarcoma, Bladder and RCC.

          3. Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1

          4. Acceptable liver function:

               -  Total bilirubin ≤ 1.5 times the upper limit of normal (ULN); for patients with
                  hepatocellular carcinoma only, total bilirubin ≤ 3 mg/dL (i.e. Child-Pugh Score
                  for bilirubin is no greater than 2).

               -  Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and alkaline
                  phosphatase (ALP) ≤ 5 x ULN.

          5. Acceptable renal function:

             • Serum creatinine ≤ 1.5 times the ULN, or calculated creatinine clearance ≥ 60
             mL/min/1.73 m2 for patients with creatinine levels above 1.5 times the institutional
             normal

          6. Acceptable hematological status:

               -  Absolute Neutrophil Count (ANC) ≥ 1500 cells/mm3

               -  Platelet count ≥ 100,000 plts/mm3 (without transfusion); ≥ 75,000 plts/mm3 for
                  patients with hepatocellular carcinoma only. For hematologic malignancy patients
                  blood counts cited above do not apply

               -  Hemoglobin ≥ 9 g/dL

               -  For the hematologic malignancy patients, blood count values cited above do not
                  apply.

          7. Prothrombin time (PT) or International Normalized Ratio (INR) ≤ 1.25 x ULN; for
             patients with hepatocellular carcinoma only, INR &lt;1.7 or prothrombin time (PT) or &lt; 4
             seconds above ULN (i.e. Child-Pugh Score is no greater than 1 for the coagulation
             parameter); for patients with hepatocellular carcinoma only, serum albumin &gt; 2.8 g/dL
             (i.e. Child-Pugh Score for albumin is no greater than 2). For the hematologic
             malignancy patients, the coagulation and albumin status cited above do not apply

          8. For patients with hepatocellular carcinoma only, Child-Pugh Class A (score 5-6)
             disease. Score for hepatic encephalopathy must be 1; the score for ascites must be no
             greater than 2 and clinically irrelevant; for the determination of the Child-Pugh
             Class.

        Exclusion Criteria:

          1. Myocardial infarction within the past 6 months, unstable and/or symptomatic
             arrhythmia, or evidence of ischemia on ECG.

          2. Active, uncontrolled bacterial, viral, or fungal infections requiring systemic
             therapy.

          3. Pregnant or nursing women.

          4. Known infection with human immunodeficiency virus (HIV).

          5. Serious nonmalignant disease (e.g., hydronephrosis, liver failure, heart failure, or
             other conditions) that could compromise protocol objectives in the opinion of the
             investigator and/or the sponsor.

          6. Patients with recent history of hemorrhage and patients predisposed to hemorrhage due
             to coagulopathies or structural anomalies.

          7. Patients who require treatment with therapeutic doses of coumadin-type anticoagulants
             (maximum daily dose of 1mg allowed for port line patency permitted).

          8. Patients with cirrhosis classed as Child-Pugh B or C.

          9. Patients with central nervous system (CNS) metastasis. Intrathecal chemotherapy is
             allowed for patients who require CNS prophylaxis or therapy.

         10. Patients for whom dexamethasone is contraindicated.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>O'Neill VIncent, MD</last_name>
    <role>Study Director</role>
    <affiliation>Mirna Therapeutics</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Virginia G. Piper Cancer Center</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85258</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uthscsa/Ctrc</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsie University Health System</name>
      <address>
        <city>Seoul</city>
        <state>Seodaemun-Gu</state>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2013</study_first_submitted>
  <study_first_submitted_qc>April 8, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 11, 2013</study_first_posted>
  <last_update_submitted>September 26, 2016</last_update_submitted>
  <last_update_submitted_qc>September 26, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 27, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>microRNA</keyword>
  <keyword>Advanced cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

